é«åº¦ã«æ©è½ããã¶ã¤ã³ãããã²ãã ãã¹ãã¼ãã»ã«ããæ´»ç¨ãããã¸ãã¹ãã¶ã¤ã³ã«åãçµãã社å å¤æ¨ªæçµç¹ãSmartcell & Designããã²ãã ç·¨éã»åæãåãå·»ã社ä¼ç¶æ³ãæ¬ããã¸ã§ã¯ãã®æ´»åæ¦è¦ãç´¹ä»ããé£è¼ç¬¬1åã«æ¬¡ãã§ã第2åã¯ã²ãã ç·¨éã»åæã«æ³¨ç®ããå½å å¤ã§åæãç¶ãã¦ããæ¯æ¥æ°èç§å¦ç°å¢é¨ã®è¨è ã»é ç°æ¡åæ°ã«ã¤ã³ã¿ãã¥ã¼ã4æ13æ¥ã«çºå£²ãããåæ°ã®èæ¸ãåæçç©å¦ã®è¡æãã®å 容ã¨ã¨ãã«ãç£æ¥åã®æå 端ãè¡ãã¢ã¡ãªã«ã®ç¾ç¶ãæ¥æ¬ã®ããããã«ã¤ãã¦Smartcell & Designã¡ã³ãã¼ã®é»éã»ä¸ä¸ç¾éãèãã¾ããã 解èªã§ã¯ãªãâåæâã§ããã㨠ä¸ä¸ï¼DNAã®è§£æãã¼ã«ãæ®åãå§ã注ç®ããã¦ããä»ãããããâ解èªâ ããç¹å®ç®æãæå®ãã¦é¨åçã«æ¸ãæããâã²ãã ç·¨éâãè¶ ããä¸ããæ§ç¯ãã¦æ°ããã²ãã ãã¤ããæå 端æè¡âã²ãã åæâã«æ³¨ç®ããã¦ããé ç°ããã¨ãã²ã
Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
At the conference, researchers presented data from a number of studies using molecular diagnostic tools to better characterize breast cancer recurrence and treatment outcomes.
Tunable synthetic phenotypic diversification on Waddingtonâs landscape through autonomous signaling Ryoji Sekine, Masayuki Yamamura, Shotaro Ayukawa, Kana Ishimatsu, Satoru Akama, Masahiro Takinoue, Masami Hagiya, and Daisuke Kiga aDepartment of Computational Intelligence and Systems Science, Tokyo Institute of Technology, Kanagawa 226-8503, Japan; bDepartment of Computer Science, University of To
ãè¦ç¹ã çå½ã®çºçç¾è±¡ãiPSåã表ããå°å½¢ãã®å®æ ã解æ åçå»çãç©è³ªçç£ã¸ã®å¿ç¨ãçºçç¾è±¡ã®ããæ·±ãç解ã«è²¢ç® æ±äº¬å·¥æ¥å¤§å¦ 大å¦é¢ç·åçå·¥å¦ç 究ç§ã®æ¨è³ 大ä»ãåææï¼ï¼ªï¼³ï¼´ ããããç 究è å ¼ä»»ï¼ã¨é¢æ ¹ 亮äºãé¢çãã¯ãåæçç©å¦æ³¨ï¼)ã®ææ³ãç¨ããçå½ã®çºçã人工å¤è½æ§å¹¹ç´°èï¼ï½ï¼°ï¼³ï¼åã表ããå°å½¢ããç´°èå ã«ããã°ã©ãã³ã°ããç´°èã®ç¶æ å¤åããã¶ã¤ã³ããæ°è¦ãªææ³ãæã¡ç«ã¦ããã¨ã«æåãããæ¨è³åææãã¯çããç´°èå ã«ã人工çã«çµã¿åãããéºä¼åã®ãããã¯ã¼ã¯ãå°å ¥ãããã®ç´°èãç´°èå ã»ç´°èéã®éºä¼åç¸äºä½ç¨ã®çµæã«ããå¤æ§ãªç´°èã¸ã¨ãè¨è¨éãã«åå²ãã¦ãããã¨ã確èªããã å¾æ¥ãåç²¾åµã¨ããï¼ã¤ã®ç´°èããå¤æ§ãªç´°èãçããçºçã®éç¨ã¯ãã¯ãã£ã³ãã³å°å½¢ãã¨ãããä¸ãã»ã©è°·ã®æ°ãå¢ãã¦ããå°å½¢ã®ä¸ãçã転ãããã¨ã§èª¬æããã¦ããï¼å³ï¼ï¼ã京é½å¤§å¦ã®å±±ä¸ææã¯ãï½ï¼°ï¼³ç´°èã®æ¦å¿µ
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend peopleâs lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
ãã¤ã³ã ã°ãªã¼ã³ã¤ããã¼ã·ã§ã³ã®èª²é¡ãç°å¢æµåä½ç¨é«ããæ¤ç©ã®ã²ãã è¨è¨ããåé ä¸çä¸ã®ç 究è ããã²ãã è¨è¨çè«ãã³ã³ãã¹ãå½¢å¼ã§èç©ãéåç¥ã¨ãã¦å ±æå ç 究è ã«éããé«æ ¡çãåå ã§ããããã¼ãã£ã«ã©ãã§ã®äººæè²æåã³ã³ãã¹ã ç¬ç«è¡æ¿æ³äººçåå¦ç 究æï¼éä¾è¯æ²»çäºé·ï¼ã®çå½æ å ±åºç¤ç 究é¨éï¼è±ç°å²éé¨éé·ï¼ã¯ããã²ãã ã®è¨è¨å³ãåççã«ãã¶ã¤ã³ããæè½ããã¦ã§ãä¸ã§ç«¶ãããä¸çåã®å½éç§å¦æè¡ã³ã³ãã¹ãã§ãããåççã²ãã è¨è¨â»1ã³ã³ãã¹ãï¼GenoConï¼ããã2010å¹´5æ25æ¥ãã9æ30æ¥ã¾ã§çç ãµã¤ãã¹â»2ã®æ å ±åºç¤ä¸ã§éå¬ãã¾ãã GenoConã¯ãçç ãµã¤ãã¹ã«çµ±åããã¦ããã²ãã ãã¼ã¿ãã¿ã³ãã¯è³ªãã¼ã¿ãªã©ã®å ¬éãã¼ã¿ãã¼ã¹ç¾¤ãæ´»ç¨ãã¦ãæ¤ç©ã®ççæ©è½ãé«ããããã®DNAé åãåå è ã«åççã«è¨è¨ãã¦ãããã³ã³ãã¹ãã§ãã第1åç®ã¯ãã空æ°ä¸ãããã«ã ã¢ã«ããããé¤
ãªãªã¼ã¹ãé害æ å ±ãªã©ã®ãµã¼ãã¹ã®ãç¥ãã
ææ°ã®äººæ°ã¨ã³ããªã¼ã®é ä¿¡
å¦çãå®è¡ä¸ã§ã
j次ã®ããã¯ãã¼ã¯
kåã®ããã¯ãã¼ã¯
lãã¨ã§èªã
eã³ã¡ã³ãä¸è¦§ãéã
oãã¼ã¸ãéã
{{#tags}}- {{label}}
{{/tags}}